ClinicalTrials.gg
Not yet recruitingNCT07749157NOVA-BEAMUpdated Nov 5, 2026

A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis

A Phase 1 interventional study of RO7845860 in Relapsing Multiple Sclerosis, sponsored by Hoffmann-La Roche. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Updated Nov 5, 2026Start date movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 35 studies in Multiple Sclerosis by Hoffmann-La Roche — 6 open to participants now, 17 under way, 7 of them phase 3. Multiple Sclerosis · Hoffmann-La Roche.

Planned enrollment
22nd of 31
85 · median 134
Started
2026
with 1 other
Phase 1
6 of 35
1 open now
Primary completion
2031-02
later than 15 of 16 live
Registered
34th of 35
by date

Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one is the 22nd largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 15 of the 16 other live ones, and was the 34th registered.

Multiple Sclerosis

3,272 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

6 of the 35 studies in Multiple Sclerosis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Multiple Sclerosis by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS).

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RMS (i.e., relapsing-remitting multiple sclerosis [RRMS] or a secondary progressive multiple sclerosis [SPMS] where patients still experience relapses) in accordance with the revised 2017 McDonald Criteria.
  • No relapse for 30 days prior to screening and neurologically stable with no relapse during screening.
  • Expanded Disability Status Scale (EDSS) score at screening (historical EDSS not older than 6 months may be used), from 0 to 6.5 inclusive.
  • From Part 2 onwards,

    1. at least two documented clinical relapses within the last 2 years prior to screening, or
    2. one documented clinical relapse in the year prior to screening or
    3. one documented clinical relapse together with signs of Magnetic Resonance Imaging (MRI) activity (any T1 Gd+ and/or new or enlarging T2 lesion) between 12 and 24 months prior to screening.
  • Documented MRI of brain with abnormalities consistent with Multiple Sclerosis (MS) at screening.

Exclusion criteria

Exclusion Criteria:

  • History of primary progressive multiple sclerosis (PPMS) at screening.
  • Any of the following laboratory parameters:

    1. CD4 levels below lower limit of normal (LLN)
    2. (ANC) levels below LLN
    3. Serum immunoglobulin G (IgG) levels below LLN
    4. Absolute lymphocyte count \< 1000 cells per microliter (μL)
    5. B-cell levels below LLN
  • Known presence of other neurologic disorders that may mimic MS, including but not limited to, neuromyelitis optica spectrum disease, myelin oligodendrocyte antibody associated disease, Lyme disease, untreated vitamin B-12 deficiency, cerebrovascular or spinal vascular disorders, and untreated hypothyroidism.
  • cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, dermatologic, psychiatric, allergic, renal or other major diseases that in the investigator's judgement, may affect interpretation of study results or participant safety.
  • Prior treatment with Chimeric antigen receptor (CAR) T-cell therapy, gene-therapy product, total body irradiation, bone marrow transplantation, allograft organ transplant, or hematopoietic stem cell transplant at any point.
  • Inability to complete an MRI scan ( for MRI, including but not restricted to, pacemaker, cochlear implants, intracranial vascular clips, surgery within 6 weeks prior to screening coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc.) or contraindication to gadolinium administration.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Part 1: Single Ascending Dose Escalation

    Participants will receive single dose of RO7845860.

    Drug: RO7845860

  • Experimental
    Part 2: Multiple Ascending Dose Escalation

    Participants will receive multiple doses of RO7845860.

    Drug: RO7845860

  • Experimental
    Part 3: Dose Expansion

    Participants will receive multiple doses of RO7845860.

    Drug: RO7845860

Interventions

  • DrugRO7845860

    Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol.

06

What researchers measure

Primary outcomes

  1. Part 1, 2 and 3: Incidence and Severity of Adverse Events (AEs)

    Time frame: From Baseline up to approximately Week 96

  2. Part 1, 2 and 3: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: From Baseline up to approximately Week 96

Secondary outcomes

  1. Part 1, 2 and 3: Serum Concentration of RO7845860

    Time frame: At prespecified timepoints from Baseline up to approximately Week 96

  2. Part 1, 2 and 3: Percentage of Participants Achieving B-Cell Levels Below the Lower Limit of Quantitation in Blood as per Employed High-Sensitive Flow Cytometry Assay

    Time frame: From Baseline up to approximately Week 96

  3. Part 1, 2 and 3: B-Cell Levels Over Time in Blood

    Time frame: From Baseline up to approximately Week 96

  4. Parts 1, 2 and 3: Median Time to Repletion of B-Cells in Blood to the Lower Limit of Normal or to the Detection Limit of the B-cell Assays

    Time frame: From Baseline up to approximately Week 96

  5. Parts 2 and 3: Change From Baseline in B-Cell Levels in Cerebrospinal Fluid (CSF)

    Time frame: From Baseline up to approximately Week 96

  6. Parts 1, 2 and 3: Prevalence and Incidence of Anti-drug Antibodies (ADAs) to RO7845860

    Time frame: From Baseline up to approximately Week 96

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2031, 50 months later.

Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 50 months is above that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Nov 2026 → Dec 2026 and completion Feb 2031 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 6, 2026
StartEst.
Dec 14, 2026was Nov 2026
Primary completionEst.
Feb 28, 2031
CompletionEst.
Dec 28, 2031was Feb 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 23, 2026→Dec 14, 2026
Nov 5, 2026
Study completion
Feb 28, 2031→Dec 28, 2031
Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPart 1, 2 and 3: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: From Baseline up to approximately Week 96
Oct 9, 2026
Show all 2 updates
  1. Nov 5, 2026
    Start date Nov 23, 2026→Dec 14, 2026
    Study completion Feb 28, 2031→Dec 28, 2031
    + 1 other change: verification date
  2. Oct 9, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPart 1, 2 and 3: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: From Baseline up to approximately Week 96
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07749157
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Dec 14, 2026 (estimated)
Primary completion
Feb 28, 2031 (estimated)
Completion
Dec 28, 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number BP46580 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion